On May 12, 2026, Collegium Pharmaceutical completed the acquisition of AZSTARYS, a CNS stimulant for ADHD, by acquiring GPC Commave Holding, LLC and Commave Sub, LLC from Corium Therapeutics. The aggregate cash consideration was approximately $655.6 million, funded by $355.6 million of existing cash and a $300.0 million delayed draw term loan. The company may pay up to $135 million in additional consideration based on future commercial and manufacturing milestones. This filing provides the required historical financial statements of Corium and pro forma financial information. Collegium Pharmaceutical is a pharmaceutical company that develops and commercializes specialty medicines.